With 10 years now added to its repertoire, European Biosimilars Congress is really turning into a staple meeting where Biosimilars partners accumulate to address the present and future condition of Biosimilars in the Europe.
The addition of two dedicated streams at the European Biosimilars Congress meeting proved to be highly successful, providing valuable insights from two distinct groups. One group excelled in the scientific and technical aspects, offering in-depth knowledge and expertise in research and manufacturing. The other group excelled in the business and strategic aspects, providing valuable insights into market trends, commercialization strategies, and regulatory considerations. This dual-stream approach allowed participants to gain a comprehensive understanding of both the scientific and commercial aspects of the biosimilars industry. The positive response and knowledge exchange from these two specialized streams contributed to the overall success of the European Biosimilars Congress meeting.
The 2025 establishment of this meeting will enable us to keep on diving further into both the investigation of Biosimilars improvement – and the business requirements for organizations that keep on seeking FDA endorsement.
The Organizing Committee is delighted to invite you to attend the Euro Biosimilars 2025 one of its remarkable Pharmaceutical conferences, to be held during April 14-15, 2025 at Paris, France. European Biosimilars Congress is a global annual event. This Europen Biosimilars Congress 2025 will bring together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. Many biologics products are making their entry in the pharma market and experiencing a notable rise in their usage over the conventional medications.
